SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?


To: Brian Malloy who wrote (702)4/10/1999 8:06:00 PM
From: Bull-like  Read Replies (1) | Respond to of 942
 
Brian-

The key words in your post here are "short periods of time". Two issues here: 1) for the short term prediction, nobody is smart enough to know, yeah, that includes the so called "pros" of the street. For long term investors (holding for at least 2 years), this is really not an issue; 2) I think that lots of short-term investors have been running scared away from this stock, you are probably one of them. Hence, the current price of wla already reflected most of this sentiment. You are trying to profit from the short term fluctuations in price due to the psychological effect, which is fine. Others, like me, just buy a stock, like wla, when it drops to a reasonable level, and hold it for a long time. So, you don't have to know the real facts. As a matter of fact, with all due respect, I don't feel you even got the fact straight about rezulin or the lilly drug in your posting.

BTW, wla is much more than Rezulin. Happy investment.

Da bull



To: Brian Malloy who wrote (702)4/11/1999 12:24:00 AM
From: Ibexx  Read Replies (2) | Respond to of 942
 
Re. What is known is that Rezulin does have monitoring imposed.

All drugs receiving NDA approval undergo post-market monitoring (Phase IV). It surprised me that this wasn't part of your knowledge base.

You can find a lot of fundamental information about the entire drug development process from FDA's website. It would help you in making investment decisions in pharmaceutical industry.

Good trading,
Ibexx



To: Brian Malloy who wrote (702)4/12/1999 11:17:00 AM
From: blake_paterson  Read Replies (1) | Respond to of 942
 
If I were a bettin' man, I would NOT bet against the FDA imposing identical monitoring standards on any new glitazone coming to market, at least not initially.

Again, my PERSONAL opinion ONLY, and not that of my employer.